Clinical Trial

Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

Study acronym: AD Biomarker
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD). In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tablets BID.
Trial Details
NCT Number NCT07741526
Lead Sponsor Arctic Therapeutics
Collaborators: Blueskin AS
Conditions Alzheimer´s Disease
Enrollment 33 participants
Start Date 2025-10-14
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-03